ClinicalTrials.gg
RecruitingNCT07235917KYRIADUpdated Nov 4, 2026

A Study to Investigate Mibavademab in Adult Women With Functional Hypothalamic Amenorrhea

A Phase 2 interventional study of Mibavademab and Placebo in Functional Hypothalamic Amenorrhea and FHA, sponsored by Regeneron Pharmaceuticals. Recruiting at 11 sites in United States. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Regeneron Pharmaceuticals · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.
Updated Nov 4, 2026Site recruiting status changedPrimary completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
34
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies in Amenorrhea with a site in United States — 7 open to participants now, 9 under way, 1 of them phase 3. Amenorrhea · United States.

Planned enrollment
16th of 30
34 · median 37
Started
2026
the only one that year
Phase 2
9 of 43
2 open now
Registered
43rd of 43
by date

Among the 43 studies in Amenorrhea with a site in United States, this one is the 16th largest by planned enrollment of the 30 interventional ones that give a count, is the only one that started in 2026, is one of 9 in phase 2, and was the 43rd registered.

Amenorrhea

79 studies on the registry are indexed under Amenorrhea; 16 are open to participants now.

Browse Amenorrhea studies →

Open to participants now

7 of the 43 studies in Amenorrhea with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 13 Amenorrhea studies recruiting now, none (0%) set no upper age limit and 11 (85%) stop at 75 or younger; 8 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 40 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Amenorrhea with a site in United States, or all of them as a file.
02

Study summary

This study is researching an experimental drug called mibavademab (also called "study drug"). The study is focused on participants with a condition called Functional Hypothalamic Amenorrhea (FHA). FHA is a condition where a woman stops menstruating because the brain is not sending the correct hormonal signals to the ovaries, which then are not able to cycle and ovulate properly.

The aim of the study is to see how well the study drug helps the body make the hormones necessary for ovulation and reproduction, and to assess its safety.

The study is looking at several other research questions, including:

  • Whether the drug helps bone health
  • What side effects may happen from taking the study drug
  • How much study drug is in the blood at different times
  • Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)
03

Conditions studied

  • Functional Hypothalamic Amenorrhea
  • FHA

Keywords

  • Secondary amenorrhea
  • Hypothalamic Pituitary Ovarian axis
  • HPO
  • Group I ovulation disorder
  • Hypogonadotropic hypogonadal anovulation
  • Gonadotropin Releasing Hormone Deficiency
  • GnRH Suppression
  • Amenorrhea
  • Female Infertility
  • Hypoestrogenism
  • Estrogen Deficiency
  • Menstrual Dysfunction
  • Menstrual Cycle Disturbance
04

Who can participate

The criteria were revised on the registry on Oct 1, 2026. See what changed

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Diagnosis of FHA after exclusion of anatomic or organic causes of amenorrhea
  2. Has had no menstrual bleeding episode within 3 months prior to day 1, as described in the protocol
  3. Has a (BMI) ≥18.5 and \<25 kg/m\^2 at screening, or BMI ≥25 to \<30 kg/m\^2 at screening AND percentage of body fat \<23% from rigorous exercise as determined by the investigator through Standard of Care (SoC) methods (eg, skinfold thickness, DXA, bioimpedance) within 6 months of screening

Key Exclusion Criteria:

  1. Has presence of primary amenorrhea (failure to reach menarche, first menstrual cycle)
  2. Has blood estradiol ≥50 pg/mL or blood progesterone ≥1 ng/mL at screening, as described in the protocol
  3. Has uterine (eg, absence of uterus, prior endometrial ablation, endometriosis, outflow tract disorders) or ovarian conditions (eg, absence of an ovary, presence of large polycystic ovaries i.e. greater than 10 cc) that impact assessment of menses or of the HPO axis
  4. Has conditions other than FHA that may cause amenorrhea or menstrual cycle disturbances (eg, polycystic ovarian syndrome, hyperprolactinemia, primary ovarian insufficiency, untreated primary hypothyroidism, primary hyperthyroidism), as described in the protocol
  5. Polycystic ovarian morphology with an ovarian volume >10 cc on TransVaginal UltraSound (TVUS) [or TransAbdominal Pelvic Ultrasound (TAPU) if applicable] at baseline
  6. Presence of follicle ≥17 mm, evidence of ruptured follicle, and/or evidence of corpus luteum on TVUS (or TAPU if applicable) at baseline

NOTE: Other protocol-defined Inclusion/Exclusion criteria apply

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
34 participants (estimated)

Study arms

  • Experimental
    Mibavademab

    Drug: Mibavademab

  • Placebo comparator
    Placebo

    Other: Placebo

Interventions

  • Administered per the protocol

    Also known as: REGN4461

  • OtherPlacebo

    Administered per the protocol

06

What researchers measure

Primary outcomes

  1. Change from the highest serum estradiol observed during a 28-day period

    Time frame: Baseline to month 6

Secondary outcomes

  1. Change from the mean serum estradiol observed during a 28-day period

    Time frame: Baseline to month 6

  2. Occurrence of menses followed by mid-cycle serum estradiol ≥200 pg/ml and mid-luteal serum progesterone ≥7.9 ng/ml

    Time frame: At month 6

  3. Change in the highest serum estradiol

    Time frame: Baseline through 6 months

  4. Occurrence of serum estradiol ≥200 pg/ml

    Time frame: Through 6 months

  5. Number of ovulatory menstrual cycles

    Time frame: Through 6 months

  6. Number of menses with mid-luteal serum progesterone ≥7.9 ng/ml and midluteal estradiol ≥100 pg/ml

    Time frame: Through 6 months

  7. Number of menstrual cycles

    Time frame: Through 6 months

  8. Percent change in Bone Mineral Density (BMD) at the lumbar spine, as measured by Dual X-ray Absorptiometry (DXA)

    Time frame: Baseline to 6 months

  9. Absolute change in BMD at the lumbar spine, as measured by DXA

    Time frame: Baseline to 6 months

  10. Percent change in Bone Mineral Content (BMC) at the lumbar spine, as measured by DXA

    Time frame: Baseline to 6 months

  11. Absolute change in BMC at the lumbar spine, as measured by DXA

    Time frame: Baseline to 6 months

  12. Percent change in BMD at the lumbar spine, as measured by DXA in participants with baseline lumbar spine BMD Z-score <-1

    Time frame: Baseline to 6 months

  13. Absolute change in BMD at the lumbar spine, as measured by DXA, in participants with baseline lumbar spine BMD Z-score <-1

    Time frame: Baseline to 6 months

  14. Percent change in BMC at the lumbar spine, as measured by DXA, in participants with baseline lumbar spine BMD Z-score <-1

    Time frame: Baseline to 6 months

  15. Absolute change in BMC at the lumbar spine, as measured by DXA, in participants with baseline lumbar spine BMD Z-score <-1

    Time frame: Baseline to 6 months

  16. Occurrence of Treatment Emergent of Adverse Events (TEAEs)

    Time frame: Up to day 280

  17. Severity of TEAEs

    Time frame: Up to day 280

  18. Concentrations of total mibavademab in serum

    Time frame: Up to day 280

  19. Occurrence of Anti-Drug Antibodies (ADA) to mibavademab

    Time frame: Up to day 280

  20. Magnitude of ADA to mibavademab

    Time frame: Up to day 280

07

Study locations

10 of 11 sites recruiting
08

References and documents

Related links

Individual participant data

Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy

Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

Data sharing details ↗ · vivli.org

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Mar 2026 (actual). Primary completion is estimated for Jan 2028, 22 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 1, 2026: primary completion Aug 2027 → Jan 2028 and completion Dec 2027 → May 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2025
First posted
Nov 19, 2025
StartActual
Mar 11, 2026
Primary completionEst.
Jan 28, 2028was Aug 2027
CompletionEst.
May 17, 2028was Dec 2027
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added, 1 site removed. Zillan Clinical Research is now Withdrawn
Show 2 added (2 United States)
  • University of Pittsburgh · Pittsburgh, United States
  • University of Pittsburgh · Philadelphia, United States
Show 1 removed
  • University of Pittsburgh · Pittsburgh, United States
across 2 updates, Oct 1, 2026 – Nov 4, 2026
Primary completion
Aug 20, 2027→Jan 28, 2028
Oct 1, 2026
Study completion
Dec 8, 2027→May 17, 2028
Oct 1, 2026
Eligibility
5 criteria edited
What changed in the criteria
  • EditedHas had no menstrual bleeding episode within 3 months (or longer) prior to day 1, as described in the protocol
  • EditedHas a Body Mass Index (BMI) ≥18.5 and <25 kg/m\^2 at screening, or BMI ≥25 to <30 kg/m\^2 at screening AND percentage of body fat <2023% from rigorous exercise as determined by the investigator through Standard of Care (SoC) methods (eg, skinfold thickness, DXA, bioimpedance) within 6 months of screening, as described in the protocol
  • EditedHas blood estradiol ≥50 pg/mL or blood progesterone ≥1 ng/mL at screening, as described in the protocol
  • EditedHas uterine (eg, absence of uterus, prior endometrial ablation, endometriosis, outflow tract disorders) or ovarian conditions (eg, absence of an ovary, presence of large polycystic ovaries i.e. greater than 10 cc) conditions that impact assessment of menses or of the HPO axis
  • EditedHas conditions other than FHA that may cause amenorrhea or menstrual cycle disturbances (eg, polycystic ovarian syndrome, hyperprolactinemia, primary ovarian insufficiency, untreated primary hypothyroidism, primary hyperthyroidism), as described in the protocol
Oct 1, 2026
Show all 2 updates
  1. Nov 4, 2026
    1 site added, 1 site removed
    Show site
    • University of Pittsburgh · Philadelphia, United States
    Show 1 removed
    • University of Pittsburgh · Pittsburgh, United States
    + 1 other change: verification date
  2. Oct 1, 2026
    1 site added. Zillan Clinical Research is now Withdrawn
    Show site
    • University of Pittsburgh · Pittsburgh, United States
    Primary completion Aug 20, 2027→Jan 28, 2028
    Study completion Dec 8, 2027→May 17, 2028
    Eligibility 5 criteria edited
    What changed in the criteria
    • EditedHas had no menstrual bleeding episode within 3 months (or longer) prior to day 1, as described in the protocol
    • EditedHas a Body Mass Index (BMI) ≥18.5 and <25 kg/m\^2 at screening, or BMI ≥25 to <30 kg/m\^2 at screening AND percentage of body fat <2023% from rigorous exercise as determined by the investigator through Standard of Care (SoC) methods (eg, skinfold thickness, DXA, bioimpedance) within 6 months of screening, as described in the protocol
    • EditedHas blood estradiol ≥50 pg/mL or blood progesterone ≥1 ng/mL at screening, as described in the protocol
    • EditedHas uterine (eg, absence of uterus, prior endometrial ablation, endometriosis, outflow tract disorders) or ovarian conditions (eg, absence of an ovary, presence of large polycystic ovaries i.e. greater than 10 cc) conditions that impact assessment of menses or of the HPO axis
    • EditedHas conditions other than FHA that may cause amenorrhea or menstrual cycle disturbances (eg, polycystic ovarian syndrome, hyperprolactinemia, primary ovarian insufficiency, untreated primary hypothyroidism, primary hyperthyroidism), as described in the protocol
    + 4 other changes: index terms, verification date, description and conditions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07235917
Responsible party
Sponsor
First posted
Nov 19, 2025
Start date
Mar 11, 2026
Primary completion
Jan 28, 2028 (estimated)
Completion
May 17, 2028 (estimated)
Last update
Nov 4, 2026

Study contacts

Clinical Trials Administrator
Contact
clinicaltrials@regeneron.com
844-734-6643
Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mibavademab

Start the discussion